Antimicrobial resistance (AMR) is an imminent threat to global public health, spreading around the world and rapidly diminishing the efficacy of common antibiotics against widespread bacterial infections. Experts estimate that by 2050 bacterial AMR will directly contribute to over 10 million deaths annually and will amount to a staggering $100 trillion cumulative loss in global production. We are running out of drugs to treat serious and life-threatening infections and if not tackled, AMR could have a devastating impact.
Omnix Medical is a clinical-stage biopharmaceutical company developing next-generation anti-infective drugs to overcome the threat of Antimicrobial Resistance. We are determined to provide a safer, more efficient alternative to win the battle against AMR by offering therapies that are, by design, highly effective and resilient against resistance. Our novel molecules are well positioned to become the first-line treatment in cases of severe infections and save lives.
CEO: Dr. Moshik Cohen-Kutner